----

| New      York                                                       | 22-1659359                                |
|---------------------------------------------------------------------|-------------------------------------------|
| (State      or other jurisdiction of incorporation or organization) | (I.R.S.      Employer Identification No.) |

| 170      Mt. Airy Road, Basking Ridge, NJ     | 07920           |
|-----------------------------------------------|-----------------|
| (Address      of principal executive offices) | (Zip      code) |

|   | Yes   ý |   | No   o |   |
|--------|-----------------------------|--------|-----------------------|--------|

|   |  Yes      o |   | No   o |   |
|--------|------------------|--------|-----------------------|--------|

| Large      Accelerated Filer   o |   | Accelerated      Filer  o |   | Non-accelerated      Filer   o |   | Smaller      Reporting Company  ý |
|-------------------------------------------------|--------|-------------------------------------|--------|-----------------------------------------------|--------|--------------------------------------------------|

|   | Yes   o |   | No   ý |   |
|--------|------------------------|--------|----------------------------|--------|

----

|           |                                   |                                                                                                            | Page No. |
|----------------|----------------------------------------|-----------------------------------------------------------------------------------------------------------------|----------|
| PART I – | Financial      Information (unaudited) |                                                                                                            |
|           |                                   |                                                                                                            |     |
|           | ITEM      1 –                    | Financial      Statements                                                                                       |     |
|           |                                   |                                                                                                            |     |
|           |                                   | Consolidated      Balance Sheets as of September 30, 2009 and December 31,    2008                              | 1        |
|           |                                   |                                                                                                            |     |
|           |                                   | Consolidated      Statements of Operations for the Three and Nine Months Ended September 30,      2009 and 2008 | 2        |
|           |                                   |                                                                                                            |     |
|           |                                   | Consolidated      Statements of Cash Flows for the Nine Months Ended September 30, 2009 and      2008           | 3        |
|           |                                   |                                                                                                            |     |
|           |                                   | Notes      to Unaudited Consolidated Financial Statements                                                       | 4-16     |
|           |                                   |                                                                                                            |     |
|           | ITEM      2 –                    | Management's      Discussion and Analysis of Financial Condition and Results of      Operations                 | 16-30    |
|           |                                   |                                                                                                            |     |
|           | ITEM      3 –                    | Quantitative      and Qualitative Disclosures About Market Risk                                                 | 31       |
|           |                                   |                                                                                                            |     |
|           | ITEM      4 –                    | Controls      and Procedures                                                                                    | 31       |
|           |                                   |                                                                                                            |     |
| PART II– | Other      Information                 |                                                                                                            |
|           |                                   |                                                                                                            |
|           | ITEM      1 –                    | Legal      Proceedings                                                                                          | 31-32    |
|           |                                   |                                                                                                            |     |
|           | ITEM      1A –                   | Risk      Factors                                                                                               | 32       |
|           |                                   |                                                                                                            |     |
|           | ITEM      2 –                    | Unregistered      Sales of Equity Securities and Use of Proceeds                                                | 32       |
|           |                                   |                                                                                                            |     |
|           | ITEM      3 –                    | Defaults      upon Senior Securities                                                                            | 32       |
|           |                                   |                                                                                                            |     |
|           | ITEM      4 –                    | Submission      of Matters to a Vote of Security Holders                                                        | 32       |
|           |                                   |                                                                                                            |     |
|           | ITEM      5 –                    | Other      Information                                                                                          | 32       |
|           |                                   |                                                                                                            |     |
|           | ITEM      6 –                    | Exhibits                                                                                                        | 33       |
|           |                                   |                                                                                                            |     |
|           |                                   | Signatures                                                                                                      | 34       |

----

|                                                                                                                                                                                                             |   |                   |     |   |                  |   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|------------------------|----------|--------|-----------------------|--------|
|                                                                                                                                                                                                             |   | September      30,2009 |     |   | December      31,2008 |   |
| ASSETS      (Note 10)                                                                                                                                                                                            |   |                   |     |   |                  |   |
| Current      assets:                                                                                                                                                                                             |   |                   |     |   |                  |   |
| Cash      and cash equivalents                                                                                                                                                                                   |   | $                      | 14,225   |   |                  | $      | 11,547 |   |
| Accounts      receivable, net of allowance for doubtful accounts of $1,572 and $3,036 at      September 30, 2009 and December 31, 2008, respectively                                                             |   |                   | 22,907   |   |                  |   | 25,366 |   |
| Inventories                                                                                                                                                                                                      |   |                   | 2,856    |   |                  |   | 2,865 |   |
| Other      current assets                                                                                                                                                                                        |   |                   | 1,623    |   |                  |   | 2,356 |   |
| Total      current assets                                                                                                                                                                                   |   |                   | 41,611   |   |                  |   | 42,134 |   |
|                                                                                                                                                                                                             |   |                   |     |   |                  |   |   |   |
| Property,      plant and equipment at cost                                                                                                                                                                       |   |                   | 44,776   |   |                  |   | 44,736 |   |
| Less:      Accumulated depreciation and amortization                                                                                                                                                             |   |                   | 32,677   |   |                  |   | 29,395 |   |
| Property,      plant and equipment, net                                                                                                                                                                          |   |                   | 12,099   |   |                  |   | 15,341 |   |
|                                                                                                                                                                                                             |   |                   |     |   |                  |   |   |   |
| Intangible      assets, net                                                                                                                                                                                      |   |                   | 1,036    |   |                  |   | 1,429 |   |
| Other      assets                                                                                                                                                                                                |   |                   | 304      |   |                  |   | 365 |   |
| Total      assets                                                                                                                                                                                      |   | $                      | 55,050   |   |                  | $      | 59,269 |   |
|                                                                                                                                                                                                             |   |                   |     |   |                  |   |   |   |
| LIABILITIES      AND STOCKHOLDERS’      EQUITY                                                                                                                                                             |   |                   |     |   |                  |   |   |   |
| Current      liabilities:                                                                                                                                                                                        |   |                   |     |   |                  |   |   |   |
| Accounts      payable                                                                                                                                                                                            |   | $                      | 5,610    |   |                  | $      | 6,701 |   |
| Accrued      expenses                                                                                                                                                                                            |   |                   | 10,553   |   |                  |   | 11,452 |   |
| Total      current liabilities                                                                                                                                                                              |   |                   | 16,163   |   |                  |   | 18,153 |   |
| Other      long-term liabilities                                                                                                                                                                                 |   |                   | 646      |   |                  |   | 348 |   |
| Commitments      and Contingencies (Note 11)                                                                                                                                                                     |   |                   |     |   |                  |   |   |   |
|                                                                                                                                                                                                             |   |                   |     |   |                  |   |   |   |
| Stockholders’      Equity:                                                                                                                                                                                 |   |                   |     |   |                  |   |   |   |
| Common      stock, par value $.04 per share; authorized 240,000,000 shares,      issued  68,713,982 and 68,683,982  shares as of      September 30, 2009 and December 31, 2008, respectively |   |                   | 2,749    |   |                  |   | 2,747 |   |
| Additional      paid-in capital                                                                                                                                                                                  |   |                   | 147,328  |   |                  |   | 146,846 |   |
| Accumulated      deficit                                                                                                                                                                                    |   |                   | (111,765 | )      |                  |   | (108,754 | ) |
|                                                                                                                                                                                                             |   |                   | 38,312   |   |                  |   | 40,839 |   |
| Less:      Treasury stock, at cost 9,395 shares as of  September 30, 2009      and December 31, 2008                                                                                                   |   |                   | (71      | )      |                  |   | (71 | ) |
| Total      stockholders’      equity                                                                                                                                                                       |   |                   | 38,241   |   |                  |   | 40,768 |   |
| Total      liabilities and stockholders' equity                                                                                                                                                                  |   | $                      | 55,050   |   |                  | $      | 59,269 |   |
|                                                                                                                                                                                                             |   |                   |     |   |                  |   |   |   |
| See      accompanying notes to consolidated financial statements.                                                                                                                                                |   |                   |     |   |                  |

----

|                                                              |   | Three      Months ended September      30, |       |   | Nine      Months endedSeptember      30, |   |
|-------------------------------------------------------------------|--------|-------------------------------------------------|------------|--------|------------------------------------------|--------|
|                                                              |   | 2009                                            |       |   | 2008                                     |   |   | 2009 |   |   | 2008 |   |
| Revenues                                                          |   | $                                               | 43,790     |   |                                     | $      | 47,196 |   |   | $ | 137,437 |   |   | $ | 150,792 |   |
| Cost      of operations                                           |   |                                            | 32,272     |   |                                     |   | 35,970 |   |   |   | 100,603 |   |   |   | 112,342 |   |
|  Gross      profit                                           |   |                                            | 11,518     |   |                                     |   | 11,226 |   |   |   | 36,834 |   |   |   | 38,450 |   |
| Selling,      general and administrative expenses                 |   |                                            | 11,867     |   |                                     |   | 13,172 |   |   |   | 38,360 |   |   |   | 39,754 |   |
| Restructuring      and other charges                         |   |                                            | 261        |   |                                     |   | - |   |   |   | 1,139 |   |   |   | 1,653 |   |
|  Operating      loss from continuing operations              |   |                                            | (610       | )      |                                     |   | (1,946 | ) |   |   | (2,665 | ) |   |   | (2,957 | ) |
| Other      income (expense):                                      |   |                                            |       |   |                                     |   |   |   |   |   |   |   |   |   |   |   |
| Interest      expense                                             |   |                                            | -          |   |                                     |   | (3 | ) |   |   | (1 | ) |   |   | (3 | ) |
| Interest      income                                              |   |                                            | 22         |   |                                     |   | 64 |   |   |   | 66 |   |   |   | 180 |   |
| Other      expenses, net                                          |   |                                            | (133       | )      |                                     |   | (147 | ) |   |   | (334 | ) |   |   | (259 | ) |
|                                                              |   |                                            | (111       | )      |                                     |   | (86 | ) |   |   | (269 | ) |   |   | (82 | ) |
| Loss      from continuing operations before income taxes          |   |                                            | (721       | )      |                                     |   | (2,032 | ) |   |   | (2,934 | ) |   |   | (3,039 | ) |
|                                                              |   |                                            |       |   |                                     |   |   |   |   |   |   |   |   |   |   |   |
| Income      tax (benefit) expense                                 |   |                                            | (2         | )      |                                     |   | 15 |   |   |   | 36 |   |   |   | (48 | ) |
|                                                              |   |                                            |       |   |                                     |   |   |   |   |   |   |   |   |   |   |   |
| Loss      from continuing operations                              |   |                                            | (719       | )      |                                     |   | (2,047 | ) |   |   | (2,970 | ) |   |   | (2,991 | ) |
|                                                              |   |                                            |       |   |                                     |   |   |   |   |   |   |   |   |   |   |   |
| Discontinued      operations:                                     |   |                                            |       |   |                                     |   |   |   |   |   |   |   |   |   |   |   |
| Income      from discontinued operations, net of income tax       |   |                                            | -          |   |                                     |   | - |   |   |   | - |   |   |   | 212 |   |
| Loss      on sale of subsidiary                                   |   |                                            | -          |   |                                     |   | (635 | ) |   |   | (41 | ) |   |   | (355 | ) |
|                                                              |   |                                            | -          |   |                                     |   | (635 | ) |   |   | (41 | ) |   |   | (143 | ) |
| Net      loss                                                     |   | $                                               | (719       | )      |                                     | $      | (2,682 | ) |   | $ | (3,011 | ) |   | $ | (3,134 | ) |
| Basic      and diluted loss per share:                            |   |                                            |       |   |                                     |   |   |   |   |   |   |   |   |   |   |   |
| Continuing      operations                                        |   |                                            |       |   |                                     |   |   |   |   |   |   |   |   |   |   |   |
| Basic                                                             |   | $                                               | (0.01      | )      |                                     | $      | (0.03 | ) |   | $ | (0.04 | ) |   | $ | (0.04 | ) |
| Diluted                                                           |   |                                            | (0.01      | )      |                                     |   | (0.03 | ) |   |   | (0.04 | ) |   |   | (0.04 | ) |
| Discontinued      operations                                      |   |                                            |       |   |                                     |   |   |   |   |   |   |   |   |   |   |   |
| Basic                                                             |   | $                                               | -          |   |                                     | $      | (0.01 | ) |   | $ | - |   |   | $ | - |   |
| Diluted                                                           |   |                                            | -          |   |                                     |   | (0.01 | ) |   |   | - |   |   |   | - |   |
| Net      loss                                                     |   |                                            |       |   |                                     |   |   |   |   |   |   |   |   |   |   |   |
| Basic                                                             |   | $                                               | (0.01      | )      |                                     | $      | (0.04 | ) |   | $ | (0.04 | ) |   | $ | (0.05 | ) |
| Diluted                                                           |   |                                            | (0.01      | )      |                                     |   | (0.04 | ) |   |   | (0.04 | ) |   |   | (0.05 | ) |
|                                                              |   |                                            |       |   |                                     |   |   |   |   |   |   |   |   |   |   |   |
| Weighted      average number of shares:                           |   |                                            |       |   |                                     |   |   |   |   |   |   |   |   |   |   |   |
| Basic      and diluted                                            |   |                                            | 68,704,587 |   |                                     |   | 68,674,587 |   |   |   | 68,687,994 |   |   |   | 68,652,397 |   |
|                                                              |   |                                            |       |   |                                     |   |   |   |   |   |   |   |   |   |   |   |
| See      accompanying notes to consolidated financial statements. |   |                                            |       |   |                                     |   |   |   |   |   |   |   |   |   |   |   |

----

|                                                                                       |   | Nine      Months ended September 30, |   |
|--------------------------------------------------------------------------------------------|--------|-------------------------------------------|--------|
|                                                                                       |   | 2009                                      |   |   | 2008 |   |
| Cash      flows from operating activities:                                                 |   |                                      |   |   |   |   |
| Net      loss                                                                              |   | $                                         | (3,011 | ) |   | $ | (3,134 | ) |
| Loss      from discontinued operations, net of income taxes                                |   |                                      | (41    | ) |   |   | (143 | ) |
| Loss      from continuing operations                                                       |   |                                      | (2,970 | ) |   |   | (2,991 | ) |
| Adjustments      to reconcile loss from continuing operations to net cash provided      by |   |                                      |   |   |   |   |   |   |
| (used      in) operating activities of continuing operations:                              |   |                                      |   |   |   |   |   |   |
| Depreciation                                                                               |   |                                      | 4,977  |   |   |   | 2,464 |   |
| Amortization                                                                               |   |                                      | 393    |   |   |   | 778 |   |
| Provision      for bad debt expense                                                        |   |                                      | 12     |   |   |   | 78 |   |
| Share-based      compensation expense                                                      |   |                                      | 484    |   |   |   | 301 |   |
| Loss      on disposal of fixed assets                                                      |   |                                      | 178    |   |   |   | 130 |   |
| Change      in assets and liabilities, net of effect                                       |   |                                      |   |   |   |   |   |   |
|  from      disposition of business:                                                   |   |                                      |   |   |   |   |   |   |
| Accounts      receivable                                                                   |   |                                      | 2,447  |   |   |   | (2,356 | ) |
| Inventories                                                                                |   |                                      | 9      |   |   |   | (415 | ) |
| Other      assets                                                                          |   |                                      | (171   | ) |   |   | 505 |   |
| Accounts      payable, accrued expenses and other long-term liabilities                    |   |                                      | 256    |   |   |   | (1,200 | ) |
| Net      cash provided by (used in) operating activities of continuing      operations     |   |                                      | 5,615  |   |   |   | (2,706 | ) |
| Net      cash (used in) provided by operating activities of discontinued      operations   |   |                                      | (300   | ) |   |   | 871 |   |
| Net      cash provided by (used in) operating activities                                   |   |                                      | 5,315  |   |   |   | (1,835 | ) |
|                                                                                       |   |                                      |   |   |   |   |   |   |
| Cash      flows from investing activities:                                                 |   |                                      |   |   |   |   |   |   |
| Capital      expenditures                                                                  |   |                                      | (2,463 | ) |   |   | (3,952 | ) |
| Net      cash used in investing activities of continuing operations                        |   |                                      | (2,463 | ) |   |   | (3,952 | ) |
| Net      cash provided by investing activities of discontinued      operations             |   |                                      | 83     |   |   |   | 5,205 |   |
| Net      cash (used in) provided by investing activities                                   |   |                                      | (2,380 | ) |   |   | 1,253 |   |
|                                                                                       |   |                                      |   |   |   |   |   |   |
| Cash      flows from financing activities:                                                 |   |                                      |   |   |   |   |   |   |
| Debt      financing fees                                                                   |   |                                      | (257   | ) |   |   | - |   |
| Net      cash used in financing activities of continuing operations                        |   |                                      | (257   | ) |   |   | - |   |
| Net      cash used in financing activities of discontinued    operations                   |   |                                      | -      |   |   |   | - |   |
| Net      cash used in financing activities                                                 |   |                                      | (257   | ) |   |   | - |   |
|                                                                                       |   |                                      |   |   |   |   |   |   |
| Net      increase (decrease) in cash and cash equivalents                                  |   |                                      | 2,678  |   |   |   | (582 | ) |
| Cash      and cash equivalents at beginning of period                                      |   |                                      | 11,547 |   |   |   | 11,267 |   |
| Cash      and cash equivalents at end of period                                            |   | $                                         | 14,225 |   |   | $ | 10,685 |   |
|                                                                                       |   |                                      |   |   |   |   |   |   |
| Supplemental      disclosure of non-cash investing activities:                             |   |                                      |   |   |   |   |   |   |
| Fixed      assets vouchered but not paid                                                   |   | $                                         | 172    |   |   | $ | 714 |   |
| Note      receivable on sale of subsidiary                                                 |   |                                      | -      |   |   |   | 333 |   |
| Supplemental      disclosure of cash flow information:                                     |   |                                      |   |   |   |   |   |   |
| Cash      paid during the period for:                                                      |   |                                      |   |   |   |   |   |   |
| Interest                                                                                   |   | $                                         | 1      |   |   | $ | 3 |   |
| Income      taxes                                                                          |   |                                      | 40     |   |   |   | - |   |
|                                                                                       |   |                                      |   |   |   |   |   |   |
|                                                                                       |   |                                      |   |   |   |   |   |   |
| See      accompanying notes to consolidated financial statements.                          |   |                                      |   |   |   |   |   |   |

----

----

| Note      2: | Liquidity |
|--------------|-----------|

----

| Note      4: | Loss      Per Share |
|--------------|---------------------|

----

|                                        |   | For      the three months ended September 30, |   |   | For      the nine months ended September 30, |   |
|---------------------------------------------|--------|-----------------------------------------------|--------|--------|----------------------------------------------|--------|
|                                        |   | 2009                                          |   |   | 2008                                         |   |   | 2009 |   |   | 2008 |   |
| Expected      life (years)                  |   |                                          | 5.54   |   |                                         |   | 5.66 |   |   |   | 5.43 |   |   |   | 5.66 |   |
| Expected      volatility                    |   |                                          | 65.90  | %      |                                         |   | 59.67 | % |   |   | 85.27 | % |   |   | 49.45 | % |
| Expected      dividend yield                |   |                                          | -      |   |                                         |   | - |   |   |   | - |   |   |   | - |   |
| Risk-free      interest rate                |   |                                          | 1.67   | %      |                                         |   | 3.44 | % |   |   | 2.53 | % |   |   | 3.44 | % |
| Weighted      average fair value of options |   |                                          |   |   |                                         |   |   |   |   |   |   |   |   |   |   |   |
| granted      during the period              |   | $                                             | 0.13   |   |                                         | $      | 0.50 |   |   | $ | 0.30 |   |   | $ | 0.50 |   |

|                                           |   |                  |      |   |                                       |   |   |                                                 |   |   |                                       |   |
|------------------------------------------------|--------|-----------------------|-----------|--------|--------------------------------------------|--------|--------|------------------------------------------------------|--------|--------|--------------------------------------------|--------|
|                                           |   | Number      of Shares |      |   | WeightedAverageExercisePrice      PerShare |   |   | WeightedAverageRemainingContractualLife      (years) |   |   | AggregateIntrinsicValue(in      thousands) |   |
| Outstanding      balance at December 31, 2008  |   |                  | 6,309,000 |   |                                       | $      | 3.52   |                                                 |   |   |                                       |   |   |   |
| Granted                                        |   |                  | 725,000   |   |                                       |   | 0.43   |                                                 |   |   |                                       |   |   |   |
| Exercised                                      |   |                  | -         |   |                                       |   | -      |                                                 |   |   |                                       |   |   |   |
| Cancelled                                      |   |                  | (430,450  | )      |                                       |   | 5.36   |                                                 |   |   |                                       |   |   |   |
| Forfeitures                                    |   |                  | (371,250  | )      |                                       |   | 2.71   |                                                 |   |   |                                       |   |   |   |
| Outstanding      balance at September 30, 2009 |   |                  | 6,232,300 |   |                                       | $      | 3.08   |                                                 |   |   | 6.8                                        |   |   | $ | 553 |   |
| Options      exercisable at September 30, 2009 |   |                  | 2,526,050 |   |                                       | $      | 5.89   |                                                 |   |   | 3.8                                        |   |   | $ | 2 |   |

----

----

|                    |   | Nine      Months EndedSeptember      30, 2008 |   |
|-------------------------|--------|-----------------------------------------------|--------|
| (in      thousands)     |   |                                          |   |
| Revenues                |   | $                                             | 13,079 |   |
| Pre-tax      income     |   | $                                             | 234    |   |
| Income      tax expense |   | $                                             | 22     |   |

|                            |   | Weighted         |   |   |     |   |   |         |   |   |    |   |
|---------------------------------|--------|------------------|--------|--------|----------|--------|--------|--------------|--------|--------|---------|--------|
|                            |   | Average          |   |   | Gross    |   |   |         |   |   |    |   |
|                            |   | Useful      Life |   |   | Carrying |   |   | Accumulated  |   |   | Net     |   |
| (in      thousands)             |   | (years)          |   |   | Amount   |   |   | Amortization |   |   | Balance |   |
| At      September 30, 2009:     |   |             |   |   |     |   |   |         |   |   |    |   |
| Non-Competition      agreements |   |             | 4.7    |   |     | $      | 8,738  |         |   | $      | 8,738   |   |   | $ | - |   |
| Customer      relationships     |   |             | 9.7    |   |     |   | 12,502 |         |   |   | 11,577  |   |   |   | 925 |   |
| Trademarks      and tradenames  |   |             | 15.7   |   |     |   | 487    |         |   |   | 376     |   |   |   | 111 |   |
|                            |   |             |   |   |     | $      | 21,727 |         |   | $      | 20,691  |   |   | $ | 1,036 |   |
| At      December 31, 2008:      |   |             |   |   |     |   |   |         |   |   |    |   |   |   |   |   |
| Non-Competition      agreements |   |             | 4.7    |   |     | $      | 8,738  |         |   | $      | 8,735   |   |   | $ | 3 |   |
| Customer      relationships     |   |             | 9.7    |   |     |   | 12,502 |         |   |   | 11,207  |   |   |   | 1,295 |   |
| Trademarks      and tradenames  |   |             | 15.7   |   |     |   | 487    |         |   |   | 356     |   |   |   | 131 |   |
|                            |   |             |   |   |     | $      | 21,727 |         |   | $      | 20,298  |   |   | $ | 1,429 |   |

----

| (in      millions)     |   | 2009    |   |   | Balance      at |   |
|------------------------|--------|---------|--------|--------|-----------------|--------|
|                   |   | Charges |   |   | Payments        |   |   | September      30, 2009 |   |
| Severance              |   | $       | 0.3    |   |            | $      | (0.3 | ) |   | $ | - |   |
| Lease      Obligations |   |    | 0.4    |   |            |   | (0.1 | ) |   |   | 0.3 |   |
|                   |   | $       | 0.7    |   |            | $      | (0.4 | ) |   | $ | 0.3 |   |

|                   |   | Balance      at        |   |   | 2009     |   |   | Balance      at         |   |
|------------------------|--------|------------------------|--------|--------|----------|--------|--------|-------------------------|--------|
| (In      millions)     |   | December      31, 2008 |   |   | Payments |   |   | September      30, 2009 |   |
| Lease      Obligations |   | $                      | 0.4    |   |     | $      | (0.2   | )                       |   | $ | 0.2 |   |

----

| (In      millions)               |   | Balance      atDecember      31, 2008 |   |   | 2009Payments |   |   | Balance      atSeptember      30, 2009 |   |
|----------------------------------|--------|---------------------------------------|--------|--------|--------------|--------|--------|----------------------------------------|--------|
| Severance\Lease      Obligations |   | $                                     | 0.2    |   |         | $      | (0.1   | )                                      |   | $ | 0.1 |   |

| ·   | pay      any dividends or distributions on, or purchase, redeem or retire any      shares of any class of its capital stock or other equity      interests; |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| ·   | incur      additional indebtedness; |
|--------------------|-------------------------------------|

| ·   | sell      or otherwise dispose of any of its assets, other than in the ordinary      course of business; |
|--------------------|----------------------------------------------------------------------------------------------------------|

| ·   | create      liens on its assets; |
|--------------------|----------------------------------|

| ·   | enter      into any sale and leaseback transactions;and |
|--------------------|---------------------------------------------------------|

| ·   | enter      into transactions with any of its affiliates on other than an arm’s-length      or no less favorable basis. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------|

----

----

----

----

|  ITEM      2 | Management’s      Discussion and Analysis of Financial Condition and Results of      Operations |
|-------------------|-------------------------------------------------------------------------------------------------------|

----

| ·   | Portamedic – performs      paramedical and medical examinations of individuals on behalf of insurance      companies in connection with the offering or rating of insurance coverage      (mainly life insurance), or payment or reimbursement of      insurance; |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Heritage Labs – performs      tests of blood, urine and/or oral fluid specimens, primarily generated in      connection with the paramedical exams and wellness screenings performed by      our Portamedic and Health & Wellness services, and assembles and sells      specimen collection kits; |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Health & Wellness –      conducts wellness screenings for health management companies, including      wellness companies, disease management organizations and health plans;      and |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Hooper Holmes Services      (formerly Underwriting Solutions and Infolink) – conducts telephone      interviews of individuals seeking life insurance coverage, retrieves      medical records, and conducts inspections. It also provides risk      management solutions and underwriting services to reinsurance companies      and insurance carriers in the life, health and annuity insurance      industry. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| ·   | In      the third quarter of 2009, we introduced a new appointment scheduling      option called Instant Scheduling.  It allows insurance agents, while      completing the policy application with the applicant, to schedule the      examination utilizing our centralized scheduling center.  The new      process significantly reduces the cycle time of policy application to      policy issuance, which benefits the applicant, agent/broker and insurance      carrier. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | The      Company has introduced its National Broker & General Agency service      program which includes specialized training of our field sales      representatives to market to this growing distribution      channel.  To serve these customers, we have implemented new case      management services which link our ordering and imaging systems to many      agency management tools. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | In      January 2009, we instituted a pricing increase for Portamedic examinations      of approximately 6% for non-contract customers.  As a result of      this pricing increase, and increases received from other Portamedic      customers under contract, average revenue per exam increased approximately      4% in the nine month period ended September 30, 2009 in comparison to the      corresponding prior year period. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·  | In      early 2009, we engaged Leerink Swann, a healthcare strategic advisor, to      assess our short and long-term strategy, including assistance in creating      new sources of revenue in adjacent markets (such as healthcare) by      utilizing existing core capabilities in our operations, including      Portamedic. Leerink Swann’s analysis also identified areas of opportunity      to automate current manual processes in ordering and completing      paramedical exams.  This effort is expected to reduce costs and      errors, and increase efficiency and speed. Leerink      Swann’s  analysis will also assist us in expanding the range of      services and products offered by our Health & Wellness and Heritage      Labs service lines, with a specific focus on high value      opportunities. |
|--------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| ·   | All      of our Portamedic branch offices are now utilizing managed      scheduling.  As a result of implementing managed scheduling, the      time required to schedule an examination has been reduced significantly      relative to past procedures where examiners scheduled their own      appointments with applicants.  Our roll-out of the managed      scheduling project was completed during the third quarter of      2009. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·  | We      continue to take steps to strengthen our local sales force: including      hiring additional sales representatives, streamlining our sales tracking      systems, improving sales training, and focusing sales incentives on      increases in paramedical exams completed (i.e. unit  goals). |
|--------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·  | We      have established a quality/imaging platform for all paramedical exam      reports on a trial basis.  This platform allows us to review the      accuracy and legibility of examination reports.  This imaging      platform, which we plan to extend throughout Portamedic, is expected to      improve our quality of service tocustomers. |
|--------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·  | In      an effort to improve the speed, accuracy and consistency of services      provided to our Portamedic customers, we decided in December 2008 to begin      the development of a new customer service order tracking IT      system.  In utilizing our current IT system, we license the      software and, as such, have difficulties in quickly implementing      improvements and enhancements to the software.  Our new IT      system is expected to eliminate these difficulties and is expected to      operate at a significantly lower cost and cash outlay in the future      relative to our existing system.  Our new customer service      system is expected to cost approximately $1.1 million and is scheduled for      completion in mid-2010.  As a result of the development of this      new system, we have reduced the estimated useful life of our current IT      systems to terminate in mid-2010.  This reduction in useful life      will increase depreciation expense (non-cash charge) in 2009 by      approximately $2.7 million and in 2010 by approximately $1.2      million.  We believe that our investment in this new customer      service system will enhance the quality of service to our customers, while      improving productivity and decreasing future cash  outlay. |
|--------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | In      September 2008, we appointed a new President of Portamedic who has more      than 25 years experience as a senior executive in the insurance      industry. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | In      January 2009, Heritage Labs moved its lab facilities to a new, larger      location which is expected to increase productivity and enable new      service/product offerings, including offerings focusing outside the      paramedical exam marketplace. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Heritage      Labs has added a Medical Director to its organization to better serve our      clients with lab and mortality related issues.  This reflects      our strategy to deliver research and statistical analyses to improve our      customers’ underwritingperformance. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| ·   | Heritage      Labs continues to expand its kit assembly products and      services.  Heritage Labs is an FDA-registered Class I and Class      II medical device assembler.  Of the three laboratories      providing testing services to the insurance industry, only Heritage Labs      is licensed to assemble kits. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Heritage      Labs is marketing a line of self-collected finger stick test kits directly      to customers, under the trade name “Appraise.”  These kits test      hemoglobin A1c.  The hemoglobin A1c test is particularly      important for diabetics, who must regularly monitor their hemoglobin A1c      levels.  Heritage Labs uses two blood testing methods for      hemoglobin A1c, one for testing whole blood specimens and the other for      testing dried blood spots.  Heritage Labs is the only laboratory      worldwide which has been certified by the National Glycohemoglobin      Standardization Program for A1c testing using dried blood spot      specimens.  The test kits are currently available in retail      locations including Wal-Mart, Rite Aid, Walgreens and other locations      nationwide. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | · | the      number of paramedical examinations performed by  Portamedic; |
|--------|--------|-----------------------------------------------------------------------|

|   | · | the      average revenue per paramedicalexamination; |
|--------|--------|------------------------------------------------------|

|   | · | time      service performance, from examination order to  completion; |
|--------|--------|-----------------------------------------------------------------------|

|   | · | the      MIB Life Index data, which represents an indicator of the level of life      insurance application activity; |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------|

|   | · | the      number of health screenings completed by Health &      Wellness; |
|--------|--------|-------------------------------------------------------------------------------|

|   | · | the      number of tele-interviewing/underwriting reports we    generate; |
|--------|--------|---------------------------------------------------------------------------|

|   | · | the      number of specimens tested by HeritageLabs; |
|--------|--------|------------------------------------------------------|

|   | · | the      average revenue per specimentested; |
|--------|--------|----------------------------------------------|

|   | · | budget      to actual performance at the branch level as well as in the aggregate;      and |
|--------|--------|---------------------------------------------------------------------------------------------|

|   | · | customer      and product line profitability. |
|--------|--------|-----------------------------------------------|

----

|                                  |   | For      the Three Months EndedSeptember      30, |   |   | For      the Nine Months EndedSeptember      30, |   |
|---------------------------------------|--------|---------------------------------------------------|--------|--------|--------------------------------------------------|--------|
|    (in      thousands) |   | 2009                                              |   |   | 2008                                             |   |   | %      Change |   |   | 2009 |   |   | 2008 |   |   | %      Change |   |
|                                  |   |                                              |   |   |                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Portamedic                            |   | $                                                 | 32,432 |   |                                             | $      | 33,748 |   |   |   | -3.9 | % |   | $ | 102,072 |   |   | $ | 107,529 |   |   |   | -5.1 | % |
| Heritage      Labs                    |   |                                              | 3,571  |   |                                             |   | 3,603 |   |   |   | -0.9 | % |   |   | 11,318 |   |   |   | 12,222 |   |   |   | -7.4 | % |
| Health      and Wellness              |   |                                              | 2,486  |   |                                             |   | 1,406 |   |   |   | 76.8 | % |   |   | 6,837 |   |   |   | 4,629 |   |   |   | 47.7 | % |
| Hooper      Holmes Services           |   |                                              | 5,925  |   |                                             |   | 9,058 |   |   |   | -34.6 | % |   |   | 19,187 |   |   |   | 28,663 |   |   |   | -33.1 | % |
|    Subtotal            |   |                                              | 44,414 |   |                                             |   | 47,815 |   |   |   | - |   |   |   | 139,414 |   |   |   | 153,043 |   |   |   | - |   |
| Intercompany      eliminations(a)     |   |                                              | (624   | )      |                                             |   | (619 | ) |   |   | - |   |   |   | (1,977 | ) |   |   | (2,251 | ) |   |   | - |   |
|    Total               |   | $                                                 | 43,790 |   |                                             | $      | 47,196 |   |   |   | -7.2 | % |   | $ | 137,437 |   |   | $ | 150,792 |   |   |   | -8.9 | % |

| ·   | fewer      paramedical examinations performed in the third quarter 2009 (365,000 in      the third quarter 2009, or 5,699 per day vs. 403,000 in the      third  quarter of 2008, or 6,289 per day), and in the nine month      period ended September 30, 2009 (1,154,000 in the nine month period ended      September 30, 2009, or 6,041 per day vs. 1,281,000 in the nine month      period ended September 30, 2008, or 6,672 per  day); |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | higher      average revenue per paramedical examination in the third quarter of 2009      of approximately 3% ($89.93 in the third quarter of 2009 vs. $87.27 in the      third quarter of 2008), and in the nine month period ended September 30,      2009 a higher average revenue per paramedical examination of approximately      4% ($89.65 in the nine month period ended September 30, 2009 vs. $86.52 in      the nine month period ended September 30,2008). |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

|   | Cost      of Operations |
|--------|-------------------------|

| (in      thousands)                     |   | For      the three months ended September 30, |   |   | For      the nine months ended September 30, |   |
|-----------------------------------------|--------|-----------------------------------------------|--------|--------|----------------------------------------------|--------|
|                                    |   |                                          |   |   | As      a % of                               |   |   |   |   |   | As      a % of |   |   |   |   |   | As      a % of |   |   |   |   |   | As      a % of |   |
|                                    |   | 2009                                          |   |   | Revenues                                     |   |   | 2008 |   |   | Revenues |   |   | 2009 |   |   | Revenues |   |   | 2008 |   |   | Revenues |   |
| Portamedic/Health      & Wellness   |   | $                                             | 25,632 |   |                                         |   | 73.4 | % |   | $ | 27,502 |   |   |   | 78.2 | % |   | $ | 79,147 |   |   |   | 72.7 | % |   | $ | 84,856 |   |   |   | 75.7 | % |
| Heritage      Labs                      |   |                                          | 2,336  |   |                                         |   | 65.4 | % |   |   | 2,381 |   |   |   | 66.1 | % |   |   | 7,294 |   |   |   | 64.4 | % |   |   | 7,794 |   |   |   | 63.8 | % |
| Hooper      Holmes Services             |   |                                          | 4,952  |   |                                         |   | 83.6 | % |   |   | 6,757 |   |   |   | 74.6 | % |   |   | 16,164 |   |   |   | 84.2 | % |   |   | 21,985 |   |   |   | 76.7 | % |
|  Subtotal                          |   |                                          | 32,920 |   |                                         |   | - |   |   |   | 36,640 |   |   |   | - |   |   |   | 102,605 |   |   |   | - |   |   |   | 114,635 |   |   |   | - |   |
| Intercompany      eliminations      (a) |   |                                          | (648   | )      |                                         |   | - |   |   |   | (670 | ) |   |   | - |   |   |   | (2,002 | ) |   |   | - |   |   |   | (2,293 | ) |   |   | - |   |
|      Total     |   | $                                             | 32,272 |   |                                         |   | 73.7 | % |   | $ | 35,970 |   |   |   | 76.2 | % |   | $ | 100,603 |   |   |   | 73.2 | % |   | $ | 112,342 |   |   |   | 74.5 | % |

| (in      thousands)                               |   | For      the three months endedSeptember      30, |   |   | (Decrease) |   |   | For      the nine months endedSeptember      30, |   |   | (Decrease) |   |
|---------------------------------------------------|--------|---------------------------------------------------|--------|--------|------------|--------|--------|--------------------------------------------------|--------|--------|------------|--------|
|                                              |   | 2009                                              |   |   | 2008       |   |   | 2009      vs. 2008                               |   |   | 2009       |   |   | 2008 |   |   | 2009      vs. 2008 |   |
| Selling,      general and administrative expenses |   | $                                                 | 11,867 |   |       | $      | 13,172 |                                             |   | $      | (1,305     | )      |   | $ | 38,360 |   |   | $ | 39,754 |   |   | $ | (1,394 | ) |

|   | · | reduced      incentive compensation expense totaling $0.8 million and $1.6 million,      respectively; |
|--------|--------|--------------------------------------------------------------------------------------------------------|

|   | · | reduced      legal and general insurance costs totaling $0.1 million and $0.7 million,      respectively; |
|--------|--------|-----------------------------------------------------------------------------------------------------------|

|   | · | reduced      amortization expense resulting from certain intangible assets now fully      amortized totaling $0.1 million and $0.5 million,      respectively; |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | reduced      Portamedic regional and administrative salaries and related expenses      totaling $0.5 million and $0.7 million,  respectively; |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | · | reduced      401k employer match relating to the elimination of the 401k Company match      totaling $0.2 million and $0.4 million, respectively;  and |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | reduced | audit,      stock compensation and Board of Directors fees and expenses totaling $0.1      million and $0.2 million,respectively. |
|--------|--------|---------|-----------------------------------------------------------------------------------------------------------------------------------|

|   | The      decreases listed above were partially offset by the    following: |
|--------|----------------------------------------------------------------------------|

|   | · | increased      depreciation expense (non-cash) resulting from a reduction in the      estimated useful life of our current IT systems scheduled to be replaced      in mid 2010, totaling $0.6 million and $2.1 million,      respectively; |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | increased      consulting costs associated with retaining the services of a strategic      advisor totaling $0.0 million and $0.5 million, respectively;      and |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | increased      health insurance costs totaling $0.2 million and $0.4 million,      respectively. |
|--------|--------|--------------------------------------------------------------------------------------------------|

| ·   | restructuring      charges for employee severance and branch office closures totaling $0.3      million and $0.7 million, respectively;and |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | charges      related to legal and other costs for the Board of Director election proxy      costs totaling $0.0 million and $0.4 million,  respectively. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | restructuring      charges for employee severance and office closures totaling $0.4      million; |
|--------------------|---------------------------------------------------------------------------------------------------|

| ·   | charges      related to the early termination of an agreement with an outside      consultant utilized in our 2006 strategic review totaling $0.9 million;      and |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | severance      charges related to the resignation of our former CEO of $0.4      million. |
|--------------------|-------------------------------------------------------------------------------------------|

----

|   | Loss      from Continuing Operations |
|--------|--------------------------------------|

----

| ·   | restructuring      payments related to employee severance and lease obligations totaling $0.7      million; |
|--------------------|-------------------------------------------------------------------------------------------------------------|

| ·   | consulting      payments related to the services of a strategic advisor totaling $0.5      million; and |
|--------------------|---------------------------------------------------------------------------------------------------------|

| ·   | capital      expenditures of $2.5 million. |
|--------------------|--------------------------------------------|

| ·   | a      decrease in accounts receivable of $2.5 million from December 31, 2008;      and |
|--------------------|-----------------------------------------------------------------------------------------|

| ·   | receipt      of a $0.6 million lease incentivepayment. |
|--------------------|--------------------------------------------------------|

----

|   | Cash      Flows from Operating Activities |
|--------|-------------------------------------------|

|   | · | a      decrease in accounts receivable of $2.5 million, primarily due to      increased Portamedic cash collections.  Our consolidated days      sales outstanding (DSO), measured on a rolling 90-day basis was 47 days at      September 30, 2009, compared to 48 days at December 31, 2008 and 55 days      at September 30, 2008.  Historically, our accounts receivable      balances and our DSO are at their lowest point in December as many of our      customers utilize the remainder of their operating budgets before their      year-end budget close-out.  Our      DSO from December 31, 2008 to September 30, 2009 improved 1 day compared      to an increase of 9 days for the same period of the prior      year.  We believe our increased collection efforts in 2009,      along with our continued focus on electronic customer billing, are the      primary drivers of our improvement in our 2009 DSO relative to our      historic experience. As a result of these improvements, our allowance for      doubtful accounts, which includes a reserve for revenue reductions,      declined approximately $1.5 million since December 31, 2008, of which $0.2      million and $0.4 million was reversed to revenue during the three and nine      month periods ended September 30,2009. |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | an      increase in accounts receivable of $2.4 million, primarily due to a      reduction in Portamedic cash collections during the first nine months of      2008. Our DSO, measured on a rolling 90-day basis was 55 days at September      30, 2008, compared to 46 days at December 31, 2007;  and |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | a      decrease in accounts payable, accrued expenses and other long-term      liabilities of $1.2 million. |
|--------|--------|-------------------------------------------------------------------------------------------------------------|

|   | Cash      Flows used in Investing Activities |
|--------|----------------------------------------------|

----

| ·   | pay      any dividends or distributions on, or purchase, redeem or retire any      shares of any class of its capital stock or other equity      interests; |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | incur      additional indebtedness; |
|--------------------|-------------------------------------|

| ·   | sell      or otherwise dispose of any of its assets, other than in the ordinary      course of business; |
|--------------------|----------------------------------------------------------------------------------------------------------|

| ·   | create      liens on its assets; |
|--------------------|----------------------------------|

| ·   | enter      into any sale and leaseback transactions;and |
|--------------------|---------------------------------------------------------|

| ·   | enter      into transactions with any of its affiliates on other than an arm’s-length      or no less favorable basis. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------|

----

----

| ITEM      3 | Quantitative      and Qualitative Disclosures About MarketRisk |
|-------------|----------------------------------------------------------------|

| ITEM      4 | Controls      and Procedures |
|-------------|------------------------------|

| ITEM      1 | Legal      Proceedings |
|-------------|------------------------|

----

| ITEM      1A | Risk      Factors |
|--------------|-------------------|

| ITEM      2 | Unregistered      Sales of Equity Securities and Use ofProceeds |
|-------------|-----------------------------------------------------------------|

| ITEM      3 | Defaults      Upon Senior Securities |
|-------------|--------------------------------------|

| ITEM      4 | Submission      of Matters to a Vote of SecurityHolders |
|-------------|---------------------------------------------------------|

| ITEM      5 | Other      Information |
|-------------|------------------------|

----

| ITEM      6 | Exhibits |
|-------------|----------|

| Exhibit No. |   | Description of Exhibit                                                                                                                              |
|-------------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
|        |   |                                                                                                                                                |
|        |   |                                                                                                                                                |
|        |   |                                                                                                                                                |
| 31.1        |   | Certification      of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities      Exchange Act of 1934.                            |
|        |   |                                                                                                                                                |
| 31.2        |   | Certification      of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities      Exchange Act of 1934.                            |
|        |   |                                                                                                                                                |
| 32.1        |   | Certification      of Chief Executive Officer pursuant to Rule 13a-14(b) under the Securities      Exchange Act of 1934 and 18 U.S.C. Section 1350. |
|        |   |                                                                                                                                                |
| 32.2        |   | Certification      of Chief Financial Officer pursuant to Rule 13a-14(b) under the Securities      Exchange Act of 1934 and 18 U.S.C. Section 1350. |
|        |   |                                                                                                                                                |
|        |   |                                                                                                                                                |

----

|   |   | By:      /s/ Roy H. Bubbs                              |   |
|--------|--------|--------------------------------------------------------|--------|
|   |   | Roy      H. Bubbs                                      |   |
|   |   | Chief      Executive Officer and President             |   |
|   |   |                                                   |   |
|   |   |                                                   |   |
|   |   |                                                   |   |
|   |   | By:      /s/ Michael J. Shea                           |   |
|   |   | Michael      J. Shea                                   |   |
|   |   | Senior      Vice President and Chief Financial Officer |   |

----